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Abstract 
Abstract 
Glioma is the most common brain tumor, 
characterized by several histological and malignancy 
grade. The majority of gliomas are sporadic, but 
some familial cases have been reported (<5%). 
Despite hereditary predisposition to gliomas has 
been associated to rare inherited cancer syndromes, 
such as Li-Fraumeni and Turcot's syndromes, 
neurofibromatosis and tuberous sclerosis, not all 
familial gliomas can be explained by these 
syndromes. Most familial gliomas seem to be 
characterized by cluster of two cases, suggesting the 
involvment of low penetrance factor risks. 
Moreover, no sex-linked disorders or SNPs on the X 
chromosome have been associated with increased 
glioma risk, except for ATRX gene, whose loss-of-
function has been observed in 20 % of adult 
oligodendrogliomas and in 80 % of grade 2 and 3 
astrocytomas. Finally, the risk to inherit tumors such 
as glioma could also be related to combinations of 
multiple risk variants: besides GWAS analysis 
identified many SNPs involved in familial gliomas 
at 5p15.33 (TERT), 7p11.2 (EGFR), 8q24.21 
(CCDC26), 9p21.3 (CDKN2A/CDKN2B), 11q23.3 
(PHLDB1) and 20q13.33 (RTEL1), mutatio could be 
associated with the risk of glioma ns in POT1 gene 
and rare variants in SPAG9 and RUNDC1 genes 
could be associated with the risk of glioma. 
Keywords 
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Identity 
Note 
Primary central nervous system (CNS) tumors can 
be divided into gliomas and non-gliomas. For the 
more recent classification of gliomas (2016 WHO 
classification), see Table 1. 
Clinics 
Note 
Gliomas represent 30% of all brain and central 
nervous system (CNS) tumors and 80% of all 
malignant brain tumors. The most common and 
malignant glioma is glioblastoma multiforme 
(GBM) (Goodenberger and Jenkins, 2012). 
Although there are several histologic types of 
gliomas, the incidence rates for all sporadic gliomas 
range from 4.67 to 5.73 per 100,000 persons 
(Barbagallo et al., 2016). Gliomas are more common 
in men than in women and in white rather than in 
black population (Ostrom et al., 2013). Anyway, 
familial glioma cases are similar to sporadic ones in 
terms of gender distribution, age, morphology and 
grade as shown in Table 2 (results from Gliogene 
Consortium https://www.bcm.edu/centers/cancer-
center/research/gliogene/) (Sadetzki et al., 2013). 
Neoplastic risk 
ENVIRONMENTAL:  Some epidemiologic risk 
factors might lead to development of glioma such as 
therapeutic ionizing radiation, pesticides, smoking, 
petroleum refining or production work and 
employment in synthetic rubber manufacturing 
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(Alifieris and Trafalis, 2015). An inverse association 
between glioma incidence and allergies, atopic 
diseases and systemic infections has been reported 
by multiple groups (Goodenberger and Jenkins, 
2012).  
FAMILIARITY:   Excluding those gliomas known 
to be due to rare hereditary cancer syndromes such 
as Turcot's and Li-Fraumeni syndromes as well as 
neurofibromatosis ( NF1, NF2) or tuberous sclerosis 
(Melin et al., 2017), there is evidence that gliomas 
cluster in families. Most familial gliomas appear to 
comprise clusters of two cases, suggesting low 
penetrance and a low risk of developing additional 
gliomas (Sadetzki et al., 2013). It is currently 
thought that approximately 5-10% of patients have a 
family history of glioma (Lindor et al., 2008, 
Robertson et al., 2010). An increased risk of 
developing primary brain tumors among first-degree 
relatives of patients with gliomas has been shown 
(Robertson et al., 2010), and there is a greater risk 
for first-degree relatives of probands with a younger 
age of onset than for first-degree relatives of 
probands with later onset (Malmer et al., 2003, 
Blumenthal and Cannon-Albright, 2008), as shown 
in Table 3.  
 
Table 1. 






Atlas Genet Cytogenet Oncol Haematol. 2019; 23(6) 161 
 
 
Table 2 - Distribution of glioma cases by date of diagnosis* and selected demographic and clinical characteristics. 
*When the glioma in the proband was diagnosed from 2007 all gliomas in the family were included in the incident cases column; 
when the glioma in the proband was diagnosed before 2007 all gliomas in the family were included in the prevalent cases 
column; **Excluding three cases with unknown age at diagnosis; comparison between mean age at diagnosis of incident and 
prevalent p = 0.003; ***p-value = 0.00009 (total incidents versus prevalent); ****For 92 cases of the 831 verified tumours, tumour 
histological behavior was unknown, and for 58 cases of the 481 verified tumours from the total incident cases, tumour 
histological behavior was unknown; *****For grades I-II p-value = 0.3 (total incident versus total prevalent). [Modified from 
Sadetzki et al., 2013] 
 
Clinics 
Gliomas represent 30% of all brain and central 
nervous system (CNS) tumors and 80% of all 
malignant brain tumors. The most common and 
malignant glioma is glioblastoma multiforme 
(GBM) (Goodenberger and Jenkins, 2012). 
Although there are several histologic types of 
gliomas, the incidence rates for all sporadic gliomas 
range from 4.67 to 5.73 per 100,000 persons 
(Barbagallo et al., 2016). Gliomas are more common 
in men than in women and in white rather than in 
black population (Ostrom et al., 2013). Anyway, 
familial glioma cases are similar to sporadic ones in 
terms of gender distribution, age, morphology and 
grade as shown in Table 2 (results from Gliogene 
Consortium https://www.bcm.edu/centers/cancer-
center/research/gliogene/) (Sadetzki et al., 2013). 
Neoplastic risk 
ENVIRONMENTAL:  Some epidemiologic risk 
factors might lead to development of glioma such as 
therapeutic ionizing radiation, pesticides, smoking, 
petroleum refining or production work and 
employment in synthetic rubber manufacturing 
(Alifieris and Trafalis, 2015). An inverse association 
between glioma incidence and allergies, atopic 
diseases and systemic infections has been reported 
by multiple groups (Goodenberger and Jenkins, 
2012).  
FAMILIARITY:   Excluding those gliomas known 
to be due to rare hereditary cancer syndromes such 
as Turcot's and Li-Fraumeni syndromes as well as  
 
neurofibromatosis ( NF1, NF2) or tuberous sclerosis 
(Melin et al., 2017), there is evidence that gliomas 
cluster in families. Most familial gliomas appear to 
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comprise clusters of two cases, suggesting low 
penetrance and a low risk of developing additional 
gliomas (Sadetzki et al., 2013). It is currently 
thought that approximately 5-10% of patients have a 
family history of glioma (Lindor et al., 2008, 
Robertson et al., 2010). An increased risk of 
developing primary brain tumors among first-degree 
relatives of patients with gliomas has been shown 
(Robertson et al., 2010), and there is a greater risk 
for first-degree relatives of probands with a younger 
age of onset than for first-degree relatives of 
probands with later onset (Malmer et al., 2003, 
Blumenthal and Cannon-Albright, 2008), as shown 
in Table 3.  
Anyway, the third-degree relative risks were not 
significantly elevated for astrocytoma, GBM or for 
the two types combined (Blumenthal and Cannon-
Albright, 2008). However, familial aggregation of 
cancer can indicate a genetic etiology but may also 
indicate shared familial environmental exposures. 
Unfortunately, a multifactorial inheritance model 
could not be clearly rejected (Table 4) (de Andrade 
et al., 2001, Malmer et al., 2001, Shete et al., 2011). 
The variation in inherited risk of glioma could be 
related to combinations of multiple risk variants. 
Here, we reported the most significant variants 
(SNPs) figured out from GWASs (Table 5 and 6) 
 
 
Table 3 - Relative risks (RR) for brain tumor among: first-degree relatives of patients (A), second-degree relatives of 
patients (B), first-degree relatives of patients with early onset brain tumor (C). [Modified from Blumenthal and Cannon-
Albright, 2008].  
 
 
Table 4 - Epidemologic studies in families with gliomas and other tumors. *Utah Population  Data Base; RR=risk relative; 
CI=confidential interval; SIR=standardized incidence ratio; FDR=first-relative degree [Modified from Kyritsis et al., 2010]  
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Table 5 - Heritable variants associated with glioma risk from    GWASs. Data from Kinnersley et al., 2015, Kinnersley et al., 
2015, Melin et al., 2017, Ostrom et al., 2014.  
 
 
Table 6 - Representative recent studies describing genetic  polymorphism linked to glioma risk. OD= odd ratio [Modified 
from Kyritsis et al., 2010] 
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A particular attention goes to POT1 gene, which 
belongs to the telomere-shelterin complex. Indeed, 
Bainbridge et al. found two different mutations in 
POT1 in two families (A and B) (Bainbridge et al., 
2015). In family A, six individuals had POT1 
mutation (NM_015450:p.G95C, 
HG19:chr7:g.124503667C>A), of whom three 
developed glioma. In family B, also six individuals 
had POT1 mutation (NM_015450:p.E450X, 
HG19:chr7:g.124481048C>A) and two developed 
glioma. Moreover, they identified, in a third family 
(C), a third protein-changing mutation 
(NM_015450:p.D617Efs*8, 
HG19:chr7:g.124464068TTA>T). In families with 
POT1 mutations, they reported that the affected 
members suffered from oligodendroglioma, which is 
substantially sensitive to irradiation. Anyway, the 
association between familial glioma and POT1 
mutations still needs to be validated.  
Jalali et al. figured out that MYO19 and KIF18B 
genes and rare variants in SPAG9 and RUNDC1 are 
potentially involved in familial gliomas (Jalali et al., 
2015).  
MENDELIAN CANCER SYNDROMES:  A 
heritable genetic contribution to gliomagenesis was 
initially suggested by the increased incidence of 
these tumors in families with Mendelian cancer 
syndromes (Table 7). Although numerous familial 
cancer syndromes are associated with increased 
glioma risk, monogenic Mendelian disorders 
account for only a small proportion of adult glioma 
incidence at the population level (Ostrom et al., 
2014). However, germline mutations of PTEN, 
TP53, CDKN2A p16(INK4A)/p14(ARF), and 
CDK4 are not common events in familial glioma, but 
occasionally they may account for a subset of 
familial glioma cases (Tachibana et al., 2000). 
Several syndromes are associated to pediatric  
To date, no sex-linked disorders have been 
associated with increased glioma risk, nor has any 
SNP on the X chromosome been identified as a 
glioma risk factor in previous genome-wide  
 
association studies.  
However, somatic loss of-function mutations in the 
X chromosome gene Alpha thalassemia/mental 
retardation syndrome X-linked (ATRX) have been 
observed in 20 % of adult oligodendroglioma tumors 
and in 80 % of grade 2 and 3 astrocytomas (Osorio 
et al., 2015). 
Treatment 
Multimodal therapies including surgical resection, 
radio- and chemotherapy (Bush et al., 2017). 
Evolution 
The lower-grade gliomas can evolve towards higher-
grade ones. 
Prognosis 
Except for pilocytic astrocytomas ID: 5773>, the 
median survival of glioma patients is still poor (12-
14 months). The 5-years survival of GBM patients is 
<10%, with a final mortality rate of close to 100% 
(Roy et al., 2015). 
Cytogenetics 
Note 
Here, we reported the most karyotype abnormalities 
associated with familial gliomas found in literature 
(Table 8)  
Genes involved and 
proteins 
Note 
Many SNPs could be associated with the risk of 
glioma at 5p15.33 ( TERT), 7p11.2 ( EGFR), 
8q24.21 ( CCDC26), 9p21.3 (CDKN2A/ CDKN2B), 
11q23.3 (PHLDB1) and 20q13.33 (RTEL1), 
mutations in POT1 gene, MYO19 and KIF18B genes 
and rare variants in SPAG9 and RUNDC1 genes 
could be associated with the risk of glioma. PTEN, 
TP53, CDKN2A, and CDK4 are not common events 
in familial glioma. 
 
Table 7 -| Known germline gene mutations associated with increased risk of glioma. Data from Ostrom et al., 2014, Kyritsis 
et al., 2010. 











Table 8 -| Summary of karyotype abnormalities associated with familial gliomas found in literature.  = copy number 
alterations 
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